The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,303,041 in first-year total cost, median $225,000.
Most frequent study sections
- Special Emphasis Panel[ZAR1 YL (M1)]6
Most frequent institutions
- REVERAGEN BIOPHARMA, INC.2
- AZITRA, INC.1
- BIOSTRATEGIES, LC1
- JME GROUP, INC.1
- VALA SCIENCES, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Oral-ERT of Pompe Disease with Tobacco Seed-Derived Recombinant Acid Maltase1R43AR073522-01 | MARTINIUK, FRANK THEODORE | JME GROUP, INC., NJ | $225,000 | ZAR1 |
| 2018 | MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme1R43AR073543-01 | ACOSTA, WALTERCRAMER, CAROLE L.RADIN, DAVID | BIOSTRATEGIES, LC, AR | $225,000 | ZAR1 |
| 2018 | Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials1R43AR073547-01 | HOFFMAN, ERIC P.PACHMAN, LAUREN M. | REVERAGEN BIOPHARMA, INC., MD | $225,000 | ZAR1 |
| 2018 | Bioengineered skin microbiota for cutaneous mitigation of Netherton Syndrome1R43AR073562-01 | OH, JULIAWHITFILL, TRAVIS | AZITRA, INC., CT | $225,000 | ZAR1 |
| 2018 | The Stem Cell-Derived Muscle Function Assay: A High Throughput Screening Platform Utilizing Kinetic Image Cytometry to Discover Therapeutics for Duchenne Muscular Dystrophy1R43AR073565-01 | MCDONOUGH, PATRICK M | VALA SCIENCES, INC., CA | $225,000 | ZAR1 |
| 2018 | Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis1R43AR073541-01 | DAMSKER, JESSEMERKEL, PETER A | REVERAGEN BIOPHARMA, INC., MD | $178,041 | ZAR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.